Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis
Authors:
- Marie HudsonMHMarie Hudson
- Canadian Scleroderma Research Group (CSRG)C(Canadian Scleroderma Research Group (CSRG)
- Murray BaronMBMurray Baron
- 4 June 2013
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 32 (10) , 1467-1474
Abstract
In systemic sclerosis (SSc), impaired diffusing capacity for carbon monoxide (DLCO) can indicate interstitial lung disease (ILD), pulmonary hypertension (PH), and/or other disease manifestations, including anemia. We undertook this study to compare the various measures of DLCO in the setting of a complex disease like SSc. We analyzed the pulmonary function tests of a cohort of SSc subjects, as a whole and among subjects with isolated PH and ILD separately. Associations were assessed using Spearman correlation coefficients, Student’s t tests, and F tests by one-way ANOVA. P values <0.05 were considered statistically significant. This study included 225 subjects (mean age, 57 years; 88 % women; mean disease duration, 9.6 years; 32 % with diffuse disease, 44 % with ILD, and 17 % with PH). Mean percent predicted DLCO values were 75 % for DLCOsb and 83 % for DLCOrb. Adjustment for alveolar volume (VA) resulted in near normalization of both DLCOsb/VAsb (91 %) and DLCOrb/VArb (91 %). Subjects with ILD had significantly lower DLCOsb but not DLCOsb/VAsb, whereas those with PH had significantly lower DLCOsb and DLCOsb/VAsb. Among the various measures of DLCO, DLCOsb had the strongest and most consistent associations with clinical outcomes of interest. Adjusting for alveolar volume dampened the associations except with PH, with which DLCOsb/VAsb was more strongly associated than DLCOsb. Low DLCOsb is the most sensitive measure to detect abnormalities in gas exchange in SSc but reflects both parenchymal lung disease and pulmonary vascular disease. Low DLCOsb/VAsb is more specific for pulmonary vascular disease and should be the preferred measure of gas exchange in SSc.Keywords
This publication has 40 references indexed in Scilit:
- Practical approach to screening for scleroderma‐associated pulmonary arterial hypertensionArthritis Care & Research, 2012
- Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study PopulationThe Journal of Rheumatology, 2011
- Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohortArthritis Research & Therapy, 2010
- Changes in causes of death in systemic sclerosis, 1972–2002Annals of the Rheumatic Diseases, 2007
- Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group databaseAnnals of the Rheumatic Diseases, 2007
- Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis–associated interstitial lung disease are not predictive of disease progressionArthritis & Rheumatism, 2007
- Measuring fatigue in rheumatoid arthritis: A systematic review of scales in useArthritis Care & Research, 2007
- Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function declineArthritis Care & Research, 2006
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980